WHY PARTNER WITH US
The challenge of developing a radiopharmaceutical is not simply radiolabeling a targeting molecule. It is ensuring the resulting product behaves predictably in-vivo, can be manufactured reliably, and generates the data required to support clinical development.
Promising peptides and proteins often demonstrate strong target binding in-vitro, yet fail to translate into effective radiopharmaceuticals due to unexpected biodistribution, dose-limiting organ exposure, or operational complexity. These risks rarely emerge from a single technical decision. They arise from gaps between disciplines—chemistry, biology, dosimetry, manufacturing, and clinical planning—that must work together from the earliest stages of development.
We focus on execution that drives decisions.
Our role is to help teams build radiopharmaceutical programs that are scientifically sound, operationally realistic, and aligned with regulatory expectations. We help organizations avoid unnecessary complexity, identify development risks early, and generate the right data at the right time to support confident progression toward the clinic.
We combine deep domain expertise in radiopharmaceutical development with practical experience operating within real drug development programs—where timelines, supply chains, safety margins, and regulatory milestones define success.
We integrate into your team
We do not operate as an external vendor delivering a narrow technical service. We function as part of the development team, aligning radiopharmaceutical development with the program’s peptide/protein engineering, preclinical approach and regulatory/operational realities. That means:
-
Recommendations that reflect the full development context
-
Decisions informed by downstream consequences
-
Communication that fits naturally into program governance
-
Execution that supports—not complicates—the broader plan
Our objective is to ensure the radiopharmaceutical therapy is developed as an integrated, well-coordinated drug development program—one that progresses efficiently from early feasibility through clinical readiness.
We focus on decisions, not activities
Radiopharmaceutical development is driven by a sequence of critical decisions. We design development plans to answer specific questions that determine the next step in the program—rather than generating exploratory data that may not change the path forward. Examples include:
-
Confirming that the targeting vector delivers sufficient tumor exposure to support therapeutic dosing
-
Identifying dose-limiting normal organ uptake and defining safety margins
-
Understanding pharmacokinetics and residence time to support isotope selection and dosing strategy
-
Establishing manufacturability and formulation conditions appropriate for clinical use
The value of development work is realized only when the results change what the team does next. That is the standard we work to.
We bring operational clarity to a complex field
Developing a radiopharmaceutical therapy—whether advancing from early feasibility into IND-enabling studies or preparing for clinical evaluation—sits at the intersection of multiple specialized domains:
-
Peptide and protein engineering
-
Radiochemistry and radiopharmaceutical manufacturing
-
Pharmacology, dosimetry, and translational science
-
Regulatory, quality, and safety requirements
Many delays and risks arise not from scientific uncertainty, but from gaps in coordination between these disciplines. A targeting vector may perform well biologically, yet encounter challenges in labeling chemistry, biodistribution, manufacturability, or clinical readiness if development decisions are made in isolation.
We help teams anticipate these challenges early, align technical decisions across functions, and maintain forward momentum—especially in programs where timelines are tight and execution risk is high.
We understand both the science and the stakes
Radiopharmaceutical therapy programs often reach pivotal moments in development—before major investments, clinical transitions, manufacturing scale-up, or regulatory interactions. At those points, the consequences of uncertainty are high.
We approach each program with a clear understanding that:
-
The data must be credible
-
The execution must be reliable
-
The timeline must be realistic
-
The decisions must be defensible
Our responsibility is to help the program move forward with confidence—supported by sound science, disciplined execution, and a clear path to the next development milestone.